|
Contact:
Martha S. Lundberg, Ph.D.
National Heart, Lung, and Blood Institute
6701 Rockledge Drive - Room 8204
Bethesda, MD 20892-7940
TEL: 301-435-0513
FAX: 301-480-1335
Email: lundberm@nhlbi.nih.gov
J. Timothy Baldwin, Ph.D.
National Heart, Lung, and Blood Institute
6701 Rockledge Drive - Room 8206
Bethesda , MD 20892-7940
TEL: 301-435-0513
FAX: 301-480-1335
Email: baldwint@nhlbi.nih.gov
Effective immediately, the NHLBI will only accept new or competing renewal BRP applications with direct costs equal to or less than $1,000,000 per year.
NHLBI requires that applications requesting $500,000 or more in direct cost in any year receive prior written approval by the NHLBI before the application will be accepted for review. Letters of request must be received by the NHLBI six weeks prior to the application receipt date. Guidelines for requesting approval can be found at: http://www.nhlbi.nih.gov/funding/policies/500kweb.htm .
Please note that the NHLBI does not count Facilities and Administrative (F&A) costs on consortia against the direct cost caps.
NHLBI will consider only applications that are directly relevant to its mission: http://www.nhlbi.nih.gov/about/org/mission.htm . Areas of high programmatic interest include, but are not limited to (http://www.nhlbi.nih.gov/funding/inits/brp-areas.htm ):
- Imaging technology (NMR, MRI, ultrasound, and other imaging modalities) for specialized heart, lung, blood, and sleep applications
- Imaging agents and probes targeted to the heart, lung, blood, and sleep system
- Hardware and software development for heart, lung, blood and sleep-specific applications e.g., cardiac motion correction, 3D visualization of vascular anatomy, breathing, and blood flow
- Biological substitutes or complex tissue constructs for the treatment of heart, lung, blood and sleep diseases, including congenital defects
- Cell-based treatments guided by natural and compatible synthetic biomaterials
- Medical devices for diagnosing and treating heart, lung, blood and sleep diseases and disorders
- Analysis of data retrieved from implanted devices for the purpose of improving the treatment of heart, lung, blood and sleep diseases, host response, and development of appropriate animal models for testing heart, lung, blood and sleep devices
- Drug delivery agents and systems targeted towards the treatment of heart, lung, blood and sleep disease
- Biosensors to detect, monitor, and control (or adjust) function in the cardiovascular system, includes the design of power sources, and ex vivo sensors for cardiovascular-specific diagnostics
- Assistive technology devices to enhance mobility and improve function in those disabled by heart, lung, blood or sleep-related diseases
- Technologies that systematically measure, screen or quantify cells and molecules and their interactions, for the diagnosis, prevention, treatment or assessment of the heart, lung, blood, or sleep system
- Nanotechnology to improve imaging and biosensors that will be used for exploring cardiovascular and pulmonary problems to advance medicine
- Nanotechnology for delivery of genes or drugs to the cardiovascular and pulmonary systems
- Nanotechnology for engineering tissues for heart, lung, blood, or sleep-specific applications
- Data acquisition and management tools to define, process, query, select and present information to understand the physiological or molecular bases of biological function in normal and pathological states of the heart, lung, blood, or sleep system
- Technologies to remotely diagnose or treat heart, lung, blood, or sleep-related diseases or disorders
- Surgical tools and techniques, including image-guided cardiovascular interventions
Last updated: March 30, 2007
|
